Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Series B round brings in $38.5mm for Atara Biotherapeutics; closed at $52mm

Executive Summary

Cancer and renal disease drug developer Atara Biotherapeutics Inc. raised $38.5mm through its Series B financing. Amgen Ventures, Celgene Corp., and crossover fund EcoR1 Capital joined current shareholders Alexandria Venture Investments (AVI), DAG Ventures, Domain Associates, and Kleiner Perkins Caufield & Byers. (AVI gains representation on Atara’s board.) The round is still open and Atara hopes to add one more investor within 90 days.
Deal Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies